Indeed, the tumor immune evasion mediated by glucocorticoids synthetized by LRH-1 coupled together with the ability of this NR to maintain stemness proprieties of continue self-renewal and proliferation also in cancer cells may elect LRH-1 as a potential target in CRC therapy (Figure 2B). This evidence concerns the gene NR5A2 and cancer.